{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:51:29Z","timestamp":1791269489526,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11578-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:29:14Z","timestamp":1779193754000},"page":"8335-8354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, anticancer estimation, and computational studies of novel benzochromenoimidazopyrimidines as CDK-2 inhibitors and apoptosis stimulators"],"prefix":"10.1007","volume":"30","author":[{"given":"Fatma G.","family":"Abdulrahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa T.","family":"Sarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin S.","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.","family":"Nossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebtehal M.","family":"Husseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"11578_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/B978-0-444-64057-4.00004-1","volume":"57","author":"FMF Roleira","year":"2018","unstructured":"Roleira FMF, Varela CL, Costa SC, Tavares-da-Silva EJ (2018) Phenolic derivatives from medicinal herbs and plant extracts: Anticancer effects and synthetic approaches to modulate biological activity. Stud Nat Prod Chem 57:115\u2013156. https:\/\/doi.org\/10.1016\/B978-0-444-64057-4.00004-1","journal-title":"Stud Nat Prod Chem"},{"key":"11578_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21608\/aijpms.2024.294539.1271","volume":"5","author":"YA Shafei","year":"2025","unstructured":"Shafei YA, Sabour R, Mahfouz NM, Elzahabi HS (2025) Synthesis, biological assessment, and docking study of new pyrazolo[1,5-a]pyrimidine derivatives with potential anticancer activity. Azhar Int J Pharm Med Sci 5:288\u2013296. https:\/\/doi.org\/10.21608\/aijpms.2024.294539.1271","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"11578_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.phymed.2016.01.015","volume":"23","author":"O Cheraghi","year":"2016","unstructured":"Cheraghi O, Dehghan G, Mahdavi M, Rahbarghazi R, Rezabakhsh A, Charoudeh HN, Iranshahi M, Montazersaheb S (2016) Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells. Phytomedicine 23:398\u2013405. https:\/\/doi.org\/10.1016\/j.phymed.2016.01.015","journal-title":"Phytomedicine"},{"key":"11578_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1039\/C7CS00550D","volume":"47","author":"S Mignani","year":"2018","unstructured":"Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade A-M, Majoral J-P (2018) Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev 47:514\u2013532. https:\/\/doi.org\/10.1039\/C7CS00550D","journal-title":"Chem Soc Rev"},{"key":"11578_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2131\/jts.40.115","volume":"40","author":"M Ghasemian","year":"2015","unstructured":"Ghasemian M, Mahdavi M, Zare P, Feizi MAH (2015) Spiroquinazolinone-induced cytotoxicity and apoptosis in K562 human leukemia cells: alteration in expression levels of Bcl-2 and Bax. J Toxicol Sci 40:115\u2013126. https:\/\/doi.org\/10.2131\/jts.40.115","journal-title":"J Toxicol Sci"},{"key":"11578_CR6","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","volume":"131","author":"M Ying","year":"2018","unstructured":"Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q (2018) Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood 131:2698\u20132711. https:\/\/doi.org\/10.1182\/blood-2017-10-813139","journal-title":"Blood"},{"key":"11578_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14728214.2017.1330885","volume":"22","author":"A Abou Zahr","year":"2017","unstructured":"Abou Zahr A, Borthakur G (2017) Emerging cell cycle inhibitors for acute myeloid leukemia. Expert Opin Emerg Drugs 22:137\u2013148. https:\/\/doi.org\/10.1080\/14728214.2017.1330885","journal-title":"Expert Opin Emerg Drugs"},{"key":"11578_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061960","volume":"21","author":"L Ding","year":"2020","unstructured":"Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q (2020) The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 21:1960. https:\/\/doi.org\/10.3390\/ijms21061960","journal-title":"Int J Mol Sci"},{"key":"11578_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020412","volume":"26","author":"MM Al-Sanea","year":"2021","unstructured":"Al-Sanea MM, Obaidullah AJ, Shaker ME, Chilingaryan G, Alanazi MM, Alsaif NA, Alkahtani HM, Alsubaie SA, Abdelgawad MA (2021) A new CDK2 inhibitor with 3-hydrazonoindolin-2-one scaffold endowed with anti-breast cancer activity: design, synthesis, biological evaluation, and in silico insights. Molecules 26:412. https:\/\/doi.org\/10.3390\/molecules26020412","journal-title":"Molecules"},{"key":"11578_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1091\/mbc.e07-06-0525","volume":"19","author":"A Satyanarayana","year":"2008","unstructured":"Satyanarayana A, Hilton MB, Kaldis P (2008) p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1\/S phase DNA damage checkpoint. Mol Biol Cell 19:65\u201377. https:\/\/doi.org\/10.1091\/mbc.e07-06-0525","journal-title":"Mol Biol Cell"},{"key":"11578_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"S Tadesse","year":"2020","unstructured":"Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, Wang S (2020) Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today 25:406\u2013413. https:\/\/doi.org\/10.1016\/j.drudis.2019.12.001","journal-title":"Drug Discov Today"},{"key":"11578_CR12","doi-asserted-by":"publisher","first-page":"12361","DOI":"10.1021\/acsomega.1c01604","volume":"6","author":"AS Hassan","year":"2021","unstructured":"Hassan AS, Moustafa GO, Awad HM, Nossier ES, Mady MF (2021) Design, synthesis, anticancer evaluation, enzymatic assays, and a molecular modeling study of novel pyrazole\u2013indole hybrids. ACS Omega 6:12361\u201312374. https:\/\/doi.org\/10.1021\/acsomega.1c01604","journal-title":"ACS Omega"},{"key":"11578_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.138741","volume":"1313","author":"AF Kassem","year":"2024","unstructured":"Kassem AF, Younis A, Nossier ES, Awad HM, El-Sayed WA (2024) Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: design, synthesis, antiproliferative activity and in silico studies. J Mol Struct 1313:138741. https:\/\/doi.org\/10.1016\/j.molstruc.2024.138741","journal-title":"J Mol Struct"},{"key":"11578_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.molstruc.2018.08.104","volume":"1176","author":"S Cherukupalli","year":"2019","unstructured":"Cherukupalli S, Chandrasekaran B, Aleti RR, Sayyad N, Hampannavar GA, Merugu SR, Rachamalla HR, Banerjee R, Karpoormath R (2019) Synthesis of 4,6-disubstituted pyrazolo[3,4-d]pyrimidine analogues: cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation. J Mol Struct 1176:538\u2013551. https:\/\/doi.org\/10.1016\/j.molstruc.2018.08.104","journal-title":"J Mol Struct"},{"key":"11578_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"Whittaker SR, Mallinger A, Workman P, Clarke PA (2017) Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther 173:83\u2013105. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.008","journal-title":"Pharmacol Ther"},{"key":"11578_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072047","volume":"27","author":"WA El-Sayed","year":"2022","unstructured":"El-Sayed WA, Alminderej FM, Mounier MM, Nossier ES, Saleh SM, Kassem AF (2022) Novel 1,2,3-triazole-coumarin hybrid glycosides and their tetrazolyl analogues: design, anticancer evaluation and molecular docking targeting EGFR, VEGFR-2 and CDK-2. Molecules 27:2047. https:\/\/doi.org\/10.3390\/molecules27072047","journal-title":"Molecules"},{"key":"11578_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14:130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504","journal-title":"Nat Rev Drug Discov"},{"key":"11578_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/0929867321666141106113633","volume":"22","author":"T Chohan","year":"2014","unstructured":"Chohan T, Qian H, Pan Y, Chen J-Z (2014) Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents. Curr Med Chem 22:237\u2013263. https:\/\/doi.org\/10.2174\/0929867321666141106113633","journal-title":"Curr Med Chem"},{"key":"11578_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers7010179","volume":"7","author":"M Peyressatre","year":"2015","unstructured":"Peyressatre M, Pr\u00e9ve C, Pellerano M, Morris M (2015) Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers (Basel) 7:179\u2013237. https:\/\/doi.org\/10.3390\/cancers7010179","journal-title":"Cancers (Basel)"},{"key":"11578_CR20","doi-asserted-by":"publisher","first-page":"A44","DOI":"10.1136\/esmoopen-2018-EACR25.105","volume":"3","author":"G Greaves","year":"2018","unstructured":"Greaves G, Milani M, Byrne D, Carter R, Butterworth M, Luo X, Eyers P, Cohen G, Varadarajan S (2018) PO-061 BCL-2 family of proteins, BCL-XL and MCL-1, regulate apoptosis and cancer cell survival by different mechanisms. ESMO Open 3:A44\u2013A45. https:\/\/doi.org\/10.1136\/esmoopen-2018-EACR25.105","journal-title":"ESMO Open"},{"key":"11578_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.brainresbull.2018.01.006","volume":"137","author":"A Keskin-Aktan","year":"2018","unstructured":"Keskin-Aktan A, Akbulut KG, Yazici-Mutlu \u00c7, Sonugur G, Ocal M, Akbulut H (2018) The effects of melatonin and curcumin on the expression of SIRT2, Bcl-2 and Bax in the hippocampus of adult rats. Brain Res Bull 137:306\u2013310. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.01.006","journal-title":"Brain Res Bull"},{"key":"11578_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/ijms19010292","volume":"19","author":"A Russo","year":"2018","unstructured":"Russo A, Cardile V, Graziano A, Avola R, Bruno M, Rigano D (2018) Involvement of Bax and Bcl-2 in induction of apoptosis by essential oils of three Lebanese Salvia species in human prostate cancer cells. Int J Mol Sci 19:292. https:\/\/doi.org\/10.3390\/ijms19010292","journal-title":"Int J Mol Sci"},{"key":"11578_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1039\/c0md00116c","volume":"1","author":"A Kamal","year":"2010","unstructured":"Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, Sagar MVP, Pushpavalli SNCVL, Ray P, Pal-Bhadra M (2010) Design, synthesis and biological evaluation of imidazopyridine\/pyrimidine-chalcone derivatives as potential anticancer agents. Medchemcomm 1:355. https:\/\/doi.org\/10.1039\/c0md00116c","journal-title":"Medchemcomm"},{"key":"11578_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejmech.2015.05.037","volume":"100","author":"R Aeluri","year":"2015","unstructured":"Aeluri R, Alla M, Polepalli S, Jain N (2015) Synthesis and antiproliferative activity of imidazo[1,2-a]pyrimidine Mannich bases. Eur J Med Chem 100:18\u201323. https:\/\/doi.org\/10.1016\/j.ejmech.2015.05.037","journal-title":"Eur J Med Chem"},{"key":"11578_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.21608\/aijpms.2023.191090.1194","volume":"4","author":"G Rady","year":"2024","unstructured":"Rady G, El Deeb M, Sarg M, Shalaby A, Helwa A (2024) Imidazo- and pyrazolopyrimidine scaffolds as anticancer agents. Azhar Int J Pharm Med Sci 4:107\u2013143. https:\/\/doi.org\/10.21608\/aijpms.2023.191090.1194","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"11578_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1021\/jm00319a007","volume":"9","author":"L Almirante","year":"1966","unstructured":"Almirante L, Polo L, Provinciali E, Rugarli P, Gamba A, Olivi A, Murmann W (1966) Derivatives of imidazole II Synthesis and reactions of imidazo[1,2-\u03b1]pyrimidines and other bi- and tricyclic imidazo derivatives with analgesic, antiinflammatory, antipyretic, and anticonvulsant activity. J Med Chem 9:29\u201333. https:\/\/doi.org\/10.1021\/jm00319a007","journal-title":"J Med Chem"},{"key":"11578_CR27","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1016\/j.ejmech.2010.09.049","volume":"45","author":"TH Al-Tel","year":"2010","unstructured":"Al-Tel TH, Al-Qawasmeh RA (2010) Post Groebke\u2013Blackburn multicomponent protocol: synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents. Eur J Med Chem 45:5848\u20135855. https:\/\/doi.org\/10.1016\/j.ejmech.2010.09.049","journal-title":"Eur J Med Chem"},{"key":"11578_CR28","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.bmcl.2019.06.031","volume":"29","author":"M Mantipally","year":"2019","unstructured":"Mantipally M, Gangireddy MR, Gundla R, Badavath VN, Mandha SR, Maddipati VC (2019) Rational design, molecular docking and synthesis of novel homopiperazine linked imidazo[1,2-a]pyrimidine derivatives as potent cytotoxic and antimicrobial agents. Bioorg Med Chem Lett 29:2248\u20132253. https:\/\/doi.org\/10.1016\/j.bmcl.2019.06.031","journal-title":"Bioorg Med Chem Lett"},{"key":"11578_CR29","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1016\/j.bmc.2008.09.027","volume":"16","author":"J-B V\u00e9ron","year":"2008","unstructured":"V\u00e9ron J-B, Allouchi H, Enguehard-Gueiffier C, Snoeck R, Andrei G, De Clercq E, Gueiffier A (2008) Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): Part II. Bioorg Med Chem 16:9536\u20139545. https:\/\/doi.org\/10.1016\/j.bmc.2008.09.027","journal-title":"Bioorg Med Chem"},{"key":"11578_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1021\/jm00279a026","volume":"15","author":"MH Fisher","year":"1972","unstructured":"Fisher MH, Lusi A (1972) Imidazo[1,2-a]pyridine anthelmintic and antifungal agents. J Med Chem 15:982\u2013985. https:\/\/doi.org\/10.1021\/jm00279a026","journal-title":"J Med Chem"},{"key":"11578_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0960-894X(02)01020-X","volume":"13","author":"KC Rupert","year":"2003","unstructured":"Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC, Fahmy B, Siekierka JJ (2003) Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 13:347\u2013350. https:\/\/doi.org\/10.1016\/S0960-894X(02)01020-X","journal-title":"Bioorg Med Chem Lett"},{"key":"11578_CR32","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1021\/jm00403a018","volume":"31","author":"WA Spitzer","year":"1988","unstructured":"Spitzer WA, Victor F, Pollock GD, Hayes JS (1988) Imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyrazines: the role of nitrogen position in inotropic activity. J Med Chem 31:1590\u20131595. https:\/\/doi.org\/10.1021\/jm00403a018","journal-title":"J Med Chem"},{"key":"11578_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2720","volume":"31","author":"H Ajani","year":"2018","unstructured":"Ajani H, Jansa J, K\u00f6pr\u00fcl\u00fco\u011flu C, Hobza P, Kry\u0161tof V, Ly\u010dka A, Lepsik M (2018) Imidazo[1,2- c ]pyrimidin-5(6 H )-one as a novel core of cyclin-dependent kinase 2 inhibitors: synthesis, activity measurement, docking, and quantum mechanical scoring. J Mol Recognit 31:e2720. https:\/\/doi.org\/10.1002\/jmr.2720","journal-title":"J Mol Recognit"},{"key":"11578_CR34","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/jhet.2243","volume":"52","author":"J Jansa","year":"2015","unstructured":"Jansa J, Ly\u010dka A, Pad\u011blkov\u00e1 Z, Grepl M, Kone\u010dn\u00fd P, Hajd\u00fach M, D\u017eub\u00e1k P (2015) New imidazo[1,2- c ]pyrimidin-5(6H)-ones derived from cytosine: synthesis, structure, and cytotoxic activity. J Heterocycl Chem 52:1382\u20131389. https:\/\/doi.org\/10.1002\/jhet.2243","journal-title":"J Heterocycl Chem"},{"key":"11578_CR35","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.2174\/138161212800672804","volume":"18","author":"R Jorda","year":"2012","unstructured":"Jorda R, Paruch K, Krystof V (2012) Cyclin-dependent kinase inhibitors inspired by Roscovitine: Purine bioisosteres. Curr Pharm Des 18:2974\u20132980. https:\/\/doi.org\/10.2174\/138161212800672804","journal-title":"Curr Pharm Des"},{"key":"11578_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113309","volume":"216","author":"J Jansa","year":"2021","unstructured":"Jansa J, Jorda R, \u0160kerlov\u00e1 J, Pachl P, Pe\u0159ina M, \u0158ezn\u00ed\u010dkov\u00e1 E, Heger T, Guck\u00fd T, \u0158ez\u00e1\u010dov\u00e1 P, Ly\u010dka A, Kry\u0161tof V (2021) Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: synthesis, kinase inhibition and co-crystal structure. Eur J Med Chem 216:113309. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113309","journal-title":"Eur J Med Chem"},{"key":"11578_CR37","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.chembiol.2015.07.018","volume":"22","author":"E Anscombe","year":"2015","unstructured":"Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble MEM, Wedge SR, Endicott JA, Griffin RJ (2015) Identification and characterization of an irreversible inhibitor of CDK2. Chem Biol 22:1159\u20131164. https:\/\/doi.org\/10.1016\/j.chembiol.2015.07.018","journal-title":"Chem Biol"},{"key":"11578_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0163-7258(02)00182-1","volume":"93","author":"TG Davies","year":"2002","unstructured":"Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble MEM (2002) Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther 93:125\u2013133. https:\/\/doi.org\/10.1016\/S0163-7258(02)00182-1","journal-title":"Pharmacol Ther"},{"key":"11578_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16559-0","volume":"11","author":"CI Wells","year":"2020","unstructured":"Wells CI, Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Ingold MR, Pickett JE, Drewry DH, Pugh KM, Schwinn MK, Hwang B, Zegzouti H, Huber KVM, Cong M, Meisenheimer PL, Willson TM, Robers MB (2020) Quantifying CDK inhibitor selectivity in live cells. Nat Commun 11:2743. https:\/\/doi.org\/10.1038\/s41467-020-16559-0","journal-title":"Nat Commun"},{"key":"11578_CR40","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.chembiol.2012.06.015","volume":"19","author":"A Echalier","year":"2012","unstructured":"Echalier A, Cot E, Camasses A, Hodimont E, Hoh F, Jay P, Sheinerman F, Krasinska L, Fisher D (2012) An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity. Chem Biol 19:1028\u20131040. https:\/\/doi.org\/10.1016\/j.chembiol.2012.06.015","journal-title":"Chem Biol"},{"key":"11578_CR41","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1021\/acs.jmedchem.6b01254","volume":"60","author":"CR Coxon","year":"2017","unstructured":"Coxon CR, Anscombe E, Harnor SJ, Martin MP, Carbain B, Golding BT, Hardcastle IR, Harlow LK, Korolchuk S, Matheson CJ, Newell DR, Noble MEM, Sivaprakasam M, Tudhope SJ, Turner DM, Wang LZ, Wedge SR, Wong C, Griffin RJ, Endicott JA, Cano C (2017) Cyclin-dependent kinase (CDK) inhibitors: structure\u2013activity relationships and insights into the CDK-2 selectivity of 6-substituted 2-arylaminopurines. J Med Chem 60:1746\u20131767. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01254","journal-title":"J Med Chem"},{"key":"11578_CR42","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.4155\/fmc.13.126","volume":"5","author":"SA Patil","year":"2013","unstructured":"Patil SA, Patil R, Pfeffer LM, Miller DD (2013) Chromenes: potential new chemotherapeutic agents for cancer. Future Med Chem 5:1647\u20131660. https:\/\/doi.org\/10.4155\/fmc.13.126","journal-title":"Future Med Chem"},{"key":"11578_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ejmech.2016.07.057","volume":"123","author":"M Costa","year":"2016","unstructured":"Costa M, Dias TA, Brito A, Proen\u00e7a F (2016) Biological importance of structurally diversified chromenes. Eur J Med Chem 123:487\u2013507. https:\/\/doi.org\/10.1016\/j.ejmech.2016.07.057","journal-title":"Eur J Med Chem"},{"key":"11578_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1021\/np0704349","volume":"71","author":"J-J Chen","year":"2008","unstructured":"Chen J-J, Cho J-Y, Hwang T-L, Chen I-S (2008) Benzoic acid derivatives, acetophenones, and anti-inflammatory constituents from Melicope semecarpifolia. J Nat Prod 71:71\u201375. https:\/\/doi.org\/10.1021\/np0704349","journal-title":"J Nat Prod"},{"key":"11578_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2174\/1570180814666171027160854","volume":"15","author":"HK Abd El-Mawgoud","year":"2018","unstructured":"Abd El-Mawgoud HK, Radwan HAM, El-Mariah F, El-Agrody AM (2018) Synthesis, characterization, biological activity of novel 1H-benzo[f]-chromene and 12H-benzo[f]chromeno[2,3-d]pyrimidine derivatives. Lett Drug Des Discov 15:857\u2013865. https:\/\/doi.org\/10.2174\/1570180814666171027160854","journal-title":"Lett Drug Des Discov"},{"key":"11578_CR46","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bmcl.2015.03.034","volume":"25","author":"C Bingi","year":"2015","unstructured":"Bingi C, Emmadi NR, Chennapuram M, Poornachandra Y, Kumar CG, Nanubolu JB, Atmakur K (2015) One-pot catalyst free synthesis of novel kojic acid tagged 2-aryl\/alkyl substituted-4H-chromenes and evaluation of their antimicrobial and anti-biofilm activities. Bioorg Med Chem Lett 25:1915\u20131919. https:\/\/doi.org\/10.1016\/j.bmcl.2015.03.034","journal-title":"Bioorg Med Chem Lett"},{"key":"11578_CR47","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1021\/jo047927s","volume":"70","author":"W Gregor","year":"2005","unstructured":"Gregor W, Grabner G, Adelw\u00f6hrer C, Rosenau T, Gille L (2005) Antioxidant properties of natural and synthetic chromanol derivatives: study by fast kinetics and electron spin resonance spectroscopy. J Org Chem 70:3472\u20133483. https:\/\/doi.org\/10.1021\/jo047927s","journal-title":"J Org Chem"},{"key":"11578_CR48","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00210-014-1038-5","volume":"387","author":"A Kheirollahi","year":"2014","unstructured":"Kheirollahi A, Pordeli M, Safavi M, Mashkouri S, Naimi-Jamal MR, Ardestani SK (2014) Cytotoxic and apoptotic effects of synthetic benzochromene derivatives on human cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol 387:1199\u20131208. https:\/\/doi.org\/10.1007\/s00210-014-1038-5","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11578_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/1570179414666170519150520","volume":"14","author":"TH Afifi","year":"2017","unstructured":"Afifi TH, Okasha RM, Alsherif H, Ahmed HEA, Abd-El-Aziz AS (2017) Design, synthesis, and docking studies of 4H-chromene and chromene based azo chromophores: a novel series of potent antimicrobial and anticancer agents. Curr Org Synth 14:868\u2013902. https:\/\/doi.org\/10.2174\/1570179414666170519150520","journal-title":"Curr Org Synth"},{"key":"11578_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bioorg.2019.03.059","volume":"87","author":"FF Alblewi","year":"2019","unstructured":"Alblewi FF, Okasha RM, Hritani ZM, Mohamed HM, El-Nassag MAA, Halawa AH, Mora A, Fouda AM, Assiri MA, Al-Dies A-AM, Afifi TH, El-Agrody AM (2019) Antiproliferative effect, cell cycle arrest and apoptosis generation of novel synthesized anticancer heterocyclic derivatives based 4H-benzo[h]chromene. Bioorg Chem 87:560\u2013571. https:\/\/doi.org\/10.1016\/j.bioorg.2019.03.059","journal-title":"Bioorg Chem"},{"key":"11578_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-05325-1","volume":"15","author":"NAE Youssef","year":"2025","unstructured":"Youssef NAE, Selim YA, Shaheen LA, Fadda AA, Gaffer HE, El-Hadidy SA (2025) Design and synthesis of novel pyridopyrimidine moieties linked to coumarin ring of potentially active cytotoxic agents and their docking study. Sci Rep 15:1\u201314. https:\/\/doi.org\/10.1038\/s41598-025-05325-1","journal-title":"Sci Rep"},{"key":"11578_CR52","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","volume":"29","author":"IW Flinn","year":"2005","unstructured":"Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR (2005) Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 29:1253\u20131257. https:\/\/doi.org\/10.1016\/j.leukres.2005.03.010","journal-title":"Leuk Res"},{"key":"11578_CR53","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","volume":"113","author":"MA Phelps","year":"2009","unstructured":"Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637\u20132645. https:\/\/doi.org\/10.1182\/blood-2008-07-168583","journal-title":"Blood"},{"key":"11578_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/14756366.2022.2151592","volume":"38","author":"RH Abd El-Hameed","year":"2023","unstructured":"Abd El-Hameed RH, Mohamed MS, Awad SM, Hassan BB, Khodair MAE-FF, Mansour YE (2023) Novel benzo chromene derivatives: design, synthesis, molecular docking, cell cycle arrest, and apoptosis induction in human acute myeloid leukemia HL-60 cells. J Enzyme Inhib Med Chem 38:405\u2013422. https:\/\/doi.org\/10.1080\/14756366.2022.2151592","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11578_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103329","volume":"93","author":"MH Ahagh","year":"2019","unstructured":"Ahagh MH, Dehghan G, Mehdipour M, Teimuri-Mofrad R, Payami E, Sheibani N, Ghaffari M, Asadi M (2019) Synthesis, characterization, anti-proliferative properties and DNA binding of benzochromene derivatives: increased Bax\/Bcl-2 ratio and caspase-dependent apoptosis in colorectal cancer cell line. Bioorg Chem 93:103329. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103329","journal-title":"Bioorg Chem"},{"key":"11578_CR56","volume":"9","author":"AY Hassan","year":"2012","unstructured":"Hassan AY, Said MM, Sarg MT, Al-Zahabi HS, Hussein EM (2012) 2-Thiohydantoin derivatives in the synthesis of some condensed heterocyclic compounds with expected biological activity. Life Sci J 9:1097\u20138135","journal-title":"Life Sci J"},{"key":"11578_CR57","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1055\/s-0030-1260259","volume":"22","author":"S Gosling","year":"2011","unstructured":"Gosling S, Rollin P, Tatibou\u00ebt A (2011) Thiohydantoins: selective N- and S-functionalization for Liebeskind-Srogl reaction study. Synthesis (Stuttg) 22:3649\u20133660. https:\/\/doi.org\/10.1055\/s-0030-1260259","journal-title":"Synthesis (Stuttg)"},{"key":"11578_CR58","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1002\/adsc.202000134","volume":"362","author":"EM Arce","year":"2020","unstructured":"Arce EM, Lamont SG, Davies PW (2020) Sulfenyl ynamides in gold catalysis: synthesis of oxo-functionalised 4-aminoimidazolyl fused compounds by intermolecular annulation reactions. Adv Synth Catal 362:2503\u20132509. https:\/\/doi.org\/10.1002\/adsc.202000134","journal-title":"Adv Synth Catal"},{"key":"11578_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107471","volume":"149","author":"YS Sheta","year":"2024","unstructured":"Sheta YS, Sarg MT, Abdulrahman FG, Nossier ES, Husseiny EM (2024) Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: design, synthesis, cytotoxicity evaluation, and mechanistic insights. Bioorg Chem 149:107471. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107471","journal-title":"Bioorg Chem"},{"key":"11578_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118049","volume":"298","author":"EM Husseiny","year":"2025","unstructured":"Husseiny EM, Sarg MT, Sheta YS, Sayed MM, Abdulrahman FG (2025) Design, synthesis, radiolabeling, and mechanistic insights of hydrazinyl imidazolones as broad spectrum antitumor agents with potential carbonic anhydrase inhibition: in vitro, in vivo, and in silico studies. Eur J Med Chem 298:118049. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118049","journal-title":"Eur J Med Chem"},{"key":"11578_CR61","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1007\/s11164-022-04847-x","volume":"48","author":"SP Patil","year":"2022","unstructured":"Patil SP, Shinde SK, Patil SS (2022) Coconut endocarp shell ash (CESA): a non-conventional catalyst for green synthesis of 2-amino-4H-benzochromenes. Res Chem Intermed 48:5003\u20135027. https:\/\/doi.org\/10.1007\/s11164-022-04847-x","journal-title":"Res Chem Intermed"},{"key":"11578_CR62","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/jhet.5570450649","volume":"45","author":"D Zhou","year":"2008","unstructured":"Zhou D, Ren Z, Cao W, Chen J, Deng H (2008) Solvent-free one-pot approach for synthesis of substituted 2-aminochromenes. J Heterocycl Chem 45:1865","journal-title":"J Heterocycl Chem"},{"key":"11578_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2020.115228","author":"M Akbarian","year":"2021","unstructured":"Akbarian M, Sanchooli E, Oveisi AR, Daliran S (2021) Choline chloride-coated UiO-66-Urea MOF: a novel multifunctional heterogeneous catalyst for efficient one-pot three-component synthesis of 2-amino-4H-chromenes. J Mol Liq. https:\/\/doi.org\/10.1016\/j.molliq.2020.115228","journal-title":"J Mol Liq"},{"key":"11578_CR64","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/jhet.3564","volume":"56","author":"UP Patil","year":"2019","unstructured":"Patil UP, Patil RC, Patil SS (2019) An eco-friendly catalytic system for one-pot multicomponent synthesis of diverse and densely functionalized pyranopyrazole and benzochromene derivatives. J Heterocycl Chem 56:1898\u20131913. https:\/\/doi.org\/10.1002\/jhet.3564","journal-title":"J Heterocycl Chem"},{"key":"11578_CR65","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00706-011-0657-5","volume":"143","author":"SP Patil","year":"2012","unstructured":"Patil SP, Kazi MA, Kanawade SB, Nikam PS, Jachak MN, Toche RB (2012) Expedient approach for the synthesis of novel indenothiophene derivatives. Monatsh Chem 143:317\u2013323. https:\/\/doi.org\/10.1007\/s00706-011-0657-5","journal-title":"Monatsh Chem"},{"key":"11578_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/B978-0-12-385464-3.00002-9","volume":"102","author":"M Shiri","year":"2011","unstructured":"Shiri M, Zolfigol MA, Kruger HG, Tanbakouchian Z (2011) Friedl\u00e4nder annulation in the synthesis of azaheterocyclic compounds. Adv Heterocycl Chem 102:139\u2013227. https:\/\/doi.org\/10.1016\/B978-0-12-385464-3.00002-9","journal-title":"Adv Heterocycl Chem"},{"key":"11578_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4155\/fmc-2023-0198","volume":"16","author":"FG Abdulrahman","year":"2024","unstructured":"Abdulrahman FG, Abulkhair HS, Zidan RA, Alwakeel AI, Al-Karmalawy AA, Husseiny EM (2024) Novel benzochromenes: design, synthesis, cytotoxicity, molecular docking and mechanistic investigations. Future Med Chem 16:105\u2013123. https:\/\/doi.org\/10.4155\/fmc-2023-0198","journal-title":"Future Med Chem"},{"key":"11578_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2020.129865","volume":"1230","author":"AY Hassan","year":"2021","unstructured":"Hassan AY, El-Sebaey SA, El Deeb MA, Elzoghbi MS (2021) Potential antiviral and anticancer effect of imidazoles and bridgehead imidazoles generated by HPV-induced cervical carcinomas via reactivating the P53\/ pRb pathway and inhibition of CA IX. J Mol Struct 1230:129865. https:\/\/doi.org\/10.1016\/j.molstruc.2020.129865","journal-title":"J Mol Struct"},{"key":"11578_CR69","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"83","author":"A Monks","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. JNCI J Natl Cancer Inst 83:757\u2013766. https:\/\/doi.org\/10.1093\/jnci\/83.11.757","journal-title":"JNCI J Natl Cancer Inst"},{"key":"11578_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assayss. J Immunol Methods 65:55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"11578_CR71","doi-asserted-by":"crossref","unstructured":"L. Meijer, A. Borgne, O. Mulner, J.P.J. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J. Delcros, J. Moulinoux, Biochemical and cellular effects of roscovitine , a potent and selective inhibitor of the cyclin-dependent kinases cdc2 , cdk2 and cdk5, 536 (1997) 527\u2013536.","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x"},{"key":"11578_CR72","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/14756366.2020.1862101","volume":"36","author":"WM Eldehna","year":"2021","unstructured":"Eldehna WM, Al-Rashood ST, Al-Warhi T, Eskandrani RO, Alharbi A, El Kerdawy AM (2021) Novel oxindole\/benzofuran hybrids as potential dual CDK2\/GSK-3\u03b2 inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. J Enzyme Inhib Med Chem 36:270\u2013285. https:\/\/doi.org\/10.1080\/14756366.2020.1862101","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11578_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis flow cytometric detection of phosphatidylserine early apoptotic cells using fluorescein labelled expression on Annexin V. J Immunol Methods 184:39\u201351. https:\/\/doi.org\/10.1016\/0022-1759(95)00072-I","journal-title":"J Immunol Methods"},{"key":"11578_CR74","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9:2344\u20132353. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0324","journal-title":"Mol Cancer Ther"},{"key":"11578_CR75","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","volume":"93","author":"D Fabbro","year":"2002","unstructured":"Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O\u2019Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93:79\u201398. https:\/\/doi.org\/10.1016\/S0163-7258(02)00179-1","journal-title":"Pharmacol Ther"},{"key":"11578_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2021.131285","volume":"1247","author":"AA El-Sayed","year":"2022","unstructured":"El-Sayed AA, Nossier ES, Almehizia AA, Amr AE-GEGE (2022) Design, synthesis, anticancer evaluation and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors. J Mol Struct 1247:131285. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131285","journal-title":"J Mol Struct"},{"key":"11578_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175688","volume":"27","author":"WA El-Sayed","year":"2022","unstructured":"El-Sayed WA, Alminderej FM, Mounier MM, Nossier ES, Saleh SM, Kassem AF (2022) New 1,2,3-triazole-coumarin-glycoside hybrids and their 1,2,4-triazolyl thioglycoside analogs targeting mitochondria apoptotic pathway: synthesis, anticancer activity and docking simulation. Molecules 27:5688. https:\/\/doi.org\/10.3390\/molecules27175688","journal-title":"Molecules"},{"key":"11578_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.136358","volume":"1294","author":"AF Kassem","year":"2023","unstructured":"Kassem AF, Omar MA, Nossier ES, Awad HM, El-Sayed WA (2023) Novel pyridine-thiazolidinone-triazole hybrid glycosides targeting EGFR and CDK-2: design, synthesis, anticancer evaluation, and molecular docking simulation. J Mol Struct 1294:136358. https:\/\/doi.org\/10.1016\/j.molstruc.2023.136358","journal-title":"J Mol Struct"},{"key":"11578_CR79","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1038\/onc.2008.191","volume":"27","author":"K Bettayeb","year":"2008","unstructured":"Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L (2008) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27:5797\u20135807. https:\/\/doi.org\/10.1038\/onc.2008.191","journal-title":"Oncogene"},{"key":"11578_CR80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ddr.430340203","volume":"34","author":"MR Boyd","year":"1995","unstructured":"Boyd MR, Padl KD (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91\u2013109. https:\/\/doi.org\/10.1002\/ddr.430340203","journal-title":"Drug Dev Res"},{"key":"11578_CR81","doi-asserted-by":"publisher","first-page":"12206","DOI":"10.1039\/d2nj02061k","volume":"46","author":"EM Othman","year":"2022","unstructured":"Othman EM, Fayed EA, Husseiny EM, Abulkhair HS (2022) Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1,2,3-triazoles with potential anticancer activity. New J Chem 46:12206\u201312216. https:\/\/doi.org\/10.1039\/d2nj02061k","journal-title":"New J Chem"},{"key":"11578_CR82","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4155\/fmc-2023-0139","volume":"15","author":"EM Husseiny","year":"2023","unstructured":"Husseiny EM, Abulkhair HS, El-Hddad SS, Osama N, El-Zoghbi MS (2023) Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Med Chem 15:1213\u20131232. https:\/\/doi.org\/10.4155\/fmc-2023-0139","journal-title":"Future Med Chem"},{"key":"11578_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105968","volume":"127","author":"EM Othman","year":"2022","unstructured":"Othman EM, Fayed EA, Husseiny EM, Abulkhair HS (2022) The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia. Bioorg Chem 127:105968. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105968","journal-title":"Bioorg Chem"},{"key":"11578_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113389","volume":"218","author":"GS Hassan","year":"2021","unstructured":"Hassan GS, Georgey HH, Mohammed EZ, George RF, Mahmoud WR, Omar FA (2021) Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors. Eur J Med Chem 218:113389. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113389","journal-title":"Eur J Med Chem"},{"key":"11578_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21608\/aijpms.2022.77353.1075","volume":"2","author":"A Younes","year":"2022","unstructured":"Younes A, Shawer T, El-Sehrawi H (2022) Design, synthesis, and antiproliferative evaluation of novel pyrazolo-pyrimidine derivatives with expected cyclin-dependent kinase 2 inhibitory effect. Azhar Int J Pharm Med Sci 2:9\u201320. https:\/\/doi.org\/10.21608\/aijpms.2022.77353.1075","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"11578_CR86","doi-asserted-by":"publisher","first-page":"28.6.1","DOI":"10.1002\/0471142727.mb2806s111","volume":"111","author":"KH Kim","year":"2015","unstructured":"Kim KH, Sederstrom JM (2015) Assaying cell cycle status using flow cytometry. Curr Protoc Mol Biol 111:28.6.1-28.6.11. https:\/\/doi.org\/10.1002\/0471142727.mb2806s111","journal-title":"Curr Protoc Mol Biol"},{"key":"11578_CR87","doi-asserted-by":"publisher","first-page":"11565","DOI":"10.1039\/D3NJ01638B","volume":"47","author":"MMF Ismail","year":"2023","unstructured":"Ismail MMF, Husseiny EM, Ibrahim MH (2023) Mimicry of sorafenib: novel diarylureas as VEGFR2 inhibitors and apoptosis inducers in breast cancer. New J Chem 47:11565\u201311576. https:\/\/doi.org\/10.1039\/D3NJ01638B","journal-title":"New J Chem"},{"key":"11578_CR88","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/scipharm90030052","volume":"90","author":"EM Mohi El-Deen","year":"2022","unstructured":"Mohi El-Deen EM, Nossier ES, Karam EA (2022) New quinazolin-4(3H)-one derivatives incorporating hydrazone and pyrazole scaffolds as antimicrobial agents targeting DNA gyraze enzyme. Sci Pharm 90:52\u201370. https:\/\/doi.org\/10.3390\/scipharm90030052","journal-title":"Sci Pharm"},{"key":"11578_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28217252","volume":"28","author":"HE Hashem","year":"2023","unstructured":"Hashem HE, Amr AEGE, Almehizia AA, Naglah AM, Kariuki BM, Eassa HA, Nossier ES (2023) Nanoparticles of a pyrazolo-pyridazine derivative as potential EGFR and CDK-2 inhibitors: design, structure determination, anticancer evaluation and in silico studies. Molecules 28:7252. https:\/\/doi.org\/10.3390\/molecules28217252","journal-title":"Molecules"},{"key":"11578_CR90","doi-asserted-by":"publisher","first-page":"39250","DOI":"10.1021\/acsomega.3c04736","volume":"8","author":"DH Dawood","year":"2023","unstructured":"Dawood DH, Sayed MM, Tohamy STK, Nossier ES (2023) New thiophenyl-pyrazolyl-thiazole hybrids as DHFR inhibitors: design, synthesis, antimicrobial evaluation, molecular modeling, and biodistribution studies. ACS Omega 8:39250\u201339268. https:\/\/doi.org\/10.1021\/acsomega.3c04736","journal-title":"ACS Omega"},{"key":"11578_CR91","doi-asserted-by":"publisher","first-page":"12889","DOI":"10.1039\/d3ra01931d","volume":"13","author":"ZM Alamshany","year":"2023","unstructured":"Alamshany ZM, Algamdi EM, Othman IMM, Anwar MM, Nossier ES (2023) New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: design, synthesis, biological evaluation, and computational studies. RSC Adv 13:12889\u201312905. https:\/\/doi.org\/10.1039\/d3ra01931d","journal-title":"RSC Adv"},{"key":"11578_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25051096","volume":"25","author":"AEGE Amr","year":"2020","unstructured":"Amr AEGE, Abdel Mageid RE, El-Naggar M, Naglah AM, Nossier ES, Elsayed EA (2020) Chiral pyridine-3,5-bis- (L-phenylalaninyl-L-leucinyl) Schiff base peptides as potential anticancer agents: design, synthesis, and molecular docking studies targeting lactate dehydrogenase-A. Molecules 25:1096. https:\/\/doi.org\/10.3390\/molecules25051096","journal-title":"Molecules"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11578-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:31Z","timestamp":1791266551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11578-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11578"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11578-3","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests as defined by BMC, or other interests that might be perceived to influence the results and\/or discussion stated in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}